Halozyme Therapeutics (HALO) Net Income Growth (5y) (2015 - 2026)
Halozyme Therapeutics (HALO) Net Income Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Halozyme Therapeutics | 9.65 Bn | 9.33 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.00% |
| Dec 31, 2025 | -31.52% |
| Sep 30, 2025 | 37.08% |
| Jun 30, 2025 | 44.94% |
| Mar 31, 2025 | 84.45% |
| Dec 31, 2024 | 43.02% |
| Sep 30, 2024 | 49.54% |
| Jun 30, 2024 | 52.97% |
| Mar 31, 2024 | 111.95% |
| Dec 31, 2023 | 111.34% |
| Sep 30, 2023 | 37.63% |
| Jun 30, 2023 | 39.41% |
| Mar 31, 2023 | 28.05% |
| Dec 31, 2022 | -14.17% |
| Sep 30, 2022 | 86.26% |
| Jun 30, 2022 | 22.31% |
| Mar 31, 2022 | 30.79% |
| Dec 31, 2021 | 34.72% |
| Sep 30, 2021 | 56.81% |
| Jun 30, 2021 | 40.13% |